WeightWatchers Adapts Program for Weight-Loss Drug Users Following Oprah's Revelation
WeightWatchers, now known as WW International, has launched the WeightWatchers GLP-1 Program, offering behavioral support for individuals using weight-loss drugs such as Ozempic and Wegovy. The program aims to help consumers manage the unique behavioral needs associated with taking GLP-1 medications, providing nutritional guidance, activity targets, and tracking tools. The announcement comes after Oprah Winfrey, a board member of WW International, revealed her use of weight-loss drugs. WW International has been focusing on becoming a more digital and tech-focused weight-management company, acquiring Sequence, a telehealth platform that specializes in chronic weight management and can prescribe weight-loss drugs. The launch of the GLP-1 program reflects the growing popularity and impact of weight-loss drugs, with WW International's stock rising nearly 10% following the announcement.